Targeted inhibition of YAP by VP inhibited the binding between YAP and the IL-6 promoter, and downregulated IL-6 and IL-11 in endometrial cancer cells, resulting in lower proliferation rates (Wang J. et al., 2019), increased sensitivity to adriamycin, and 45.36% decrease in tumor weight in the treated mice (Bang et al., 2019). Here, YAP1 is linked to neoplasm.